A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT05259839. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Dose Escalation and Expansion Study of Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Multiple Myeloma
Study identification
- NCT ID
- NCT05259839
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 283 participants
Conditions and interventions
Conditions
Interventions
- Daratumumab Drug
- Dexamethasone Drug
- Etentamig Drug
- Lenalidomide Drug
- Pomalidomide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 19, 2022
- Primary completion
- Aug 31, 2033
- Completion
- Aug 31, 2033
- Last update posted
- Dec 18, 2025
2022 – 2033
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas for Medical Sciences /ID# 243096 | Little Rock | Arkansas | 72205 | — |
| Sylvester Comprehensive Cancer Center /ID# 243673 | Miami | Florida | 33136-1002 | — |
| Moffitt Cancer Center /ID# 243437 | Tampa | Florida | 33612-9416 | — |
| University of Maryland, Baltimore /ID# 243679 | Baltimore | Maryland | 21201 | — |
| Dana-Farber Cancer Institute /ID# 249529 | Boston | Massachusetts | 02215 | — |
| University of Massachusetts - Worcester /ID# 243977 | Worcester | Massachusetts | 01655 | — |
| University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 243438 | Ann Arbor | Michigan | 48109 | — |
| The Valley Hospital /ID# 243829 | Paramus | New Jersey | 07652 | — |
| Rutenberg Cancer Center /ID# 244647 | New York | New York | 10029-6030 | — |
| Memorial Sloan Kettering Cancer Center /ID# 244656 | New York | New York | 10065-6007 | — |
| Atrium Health Levine Cancer Institute /ID# 242851 | Charlotte | North Carolina | 28204 | — |
| University of Texas Southwestern Medical Center /ID# 243273 | Dallas | Texas | 75390-7208 | — |
| Huntsman Cancer Institute /ID# 242872 | Salt Lake City | Utah | 84112-5500 | — |
| University of Washington /ID# 243172 | Seattle | Washington | 98109 | — |
| Froedtert Memorial Lutheran Hospital /ID# 242654 | Milwaukee | Wisconsin | 53226-3522 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05259839, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 18, 2025 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05259839 live on ClinicalTrials.gov.